Background: Although anxiety is highly prevalent in people with bipolar disorders and has deleterious impact on the course of the illness, past reviews have shown that many aspects of the topic remain under-researched. This scoping review aims to provide a comprehensive overview of the literature addressing anxiety in bipolar disorder (A-BD) between 2011 and 2020, assess if the interest in the topic has increased over the period and map the publication trends.
Methods: Three databases were systematically searched, and all articles were screened at the title/abstract and full text level based on inclusion and exclusion criteria. Of these, 1099 articles were included in the study. The annual number of articles on A-BD published between 2011 and 2020 was calculated and articles addressing it as a primary topic (n = 310) were classified into 4 categories and 11 subcategories to identify gaps in the knowledge.
Results: The results show no clear increase in the number of annual publications during the period and much of the available literature is of a descriptive nature. Less is known about the processes underlying the comorbidity and about treatment approaches.
Limitations: Given the large scope of the research question, no quality assessment of the evidence was made. Only articles in English or French were considered.
Conclusions: These results highlight the need to change the focus of research efforts to better understand and address this unique set of conditions in clinical settings.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jad.2022.09.057 | DOI Listing |
Cannabis
December 2024
Institute for Mental Health and Policy Research, Centre for Addiction and Mental Health.
Objective: Since the federal Canadian government legalized cannabis in 2018, cannabis use in the general population has slightly increased. However, little is known about the impact of cannabis legalization on pattens of cannabis use in psychiatric populations.
Method: We studied changes in daily/almost daily and average 30-day cannabis use amongst individuals currently using cannabis who reported past 12-month experiences of specific mental health disorders and among those without past 12-month experiences of any mental health disorder before and after Canadian legalization of recreational cannabis use ( = 13,527).
Sci Data
January 2025
University of Bergen, Department of Clinical Medicine, Bergen, 5009, Norway.
Mental health is vital to human well-being, and prevention strategies to address mental illness have a significant impact on the burden of disease and quality of life. With the recent developments in body-worn sensors, it is now possible to continuously collect data that can be used to gain insights into mental health states. This has the potential to optimize psychiatric assessment, thereby improving patient experiences and quality of life.
View Article and Find Full Text PDFEcotoxicol Environ Saf
January 2025
School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China; Clinical Epidemiology Unit, Qilu Hospital of Shandong University, Jinan, China; Clinical Research Center of Shandong University, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China. Electronic address:
Background: The causal relationship between PM (particulate matter with an aerodynamic diameter ≤2.5 μm) and common mental disorders, along with its neuropathological mechanisms, remains unclear.
Methods: We used genome-wide association study datasets from the UK Biobank and Psychiatric Genomics Consortium to systematically investigate the causal relationship between PM and nine common psychiatric disorders using two-sample Mendelian randomization (TSMR) methods.
EClinicalMedicine
August 2024
Department of Psychiatry, University of Oxford, Warneford Hospital, Warneford Lane, Oxford, OX3 7JX, United Kingdom.
Background: While semaglutide, approved for type-2 diabetes mellitus (T2DM), is being investigated as a treatment for brain disorders, concerns over adverse neuropsychiatric events have emerged. More data are therefore needed to assess the effects of semaglutide on brain health. This study provides robust estimates of the risk of neurological and psychiatric outcomes following semaglutide use compared to three other antidiabetic medications.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!